Clinical trial
A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis
NCT01113333 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis
- Lead sponsor
- Sanofi
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2010
- Completion date
- February 28, 2011
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.